Core Viewpoint - Changchun High-tech has entered into an exclusive licensing agreement with Yarrow for the GenSci098 injection project, receiving an initial payment of $70 million, which enhances the company's cash reserves and supports its future R&D and internationalization strategy [1][4]. Group 1: Licensing Agreement Details - The agreement allows Yarrow to have global exclusive rights for the development, production, and commercialization of GenSci098 injection outside Greater China, specifically targeting thyroid-related eye disease (TED) and Graves' disease (GD) [3]. - Changchun High-tech's subsidiary, SaiZeng Medical, retains the rights for development and commercialization of GenSci098 in China [3]. Group 2: Product Information - GenSci098 is a humanized monoclonal antibody designed to treat hyperthyroidism by blocking the synthesis and release of thyroid hormones and preventing the proliferation of thyroid cells [2]. - The injection has shown potential in preclinical data and ongoing Phase I clinical trials for TED, with plans for further clinical development targeting GD [2]. Group 3: Financial Implications - SaiZeng Medical is expected to receive a total of $120 million in upfront and milestone payments, including the initial $70 million and an additional $50 million for recent development milestones [4]. - The agreement also includes potential milestone payments of up to $1.365 billion and over 10% sales royalties post-product launch [4].

Core Viewpoint - Changchun Gaoxin has received a $70 million upfront payment from Yarrow Bioscience for the exclusive licensing agreement related to the GenSci098 injection project, enhancing the company's cash reserves and supporting its future R&D and international strategy [1] Group 1 - Changchun Gaoxin's subsidiary, Changchun Jinsai Pharmaceutical, has a wholly-owned subsidiary, Shanghai Saizeng Medical Technology, which entered into an exclusive licensing agreement with Yarrow Bioscience for the GenSci098 injection project [1] - The agreement grants Yarrow exclusive rights to develop, produce, and commercialize GenSci098 injection globally, excluding Greater China [1] - The payment received will further strengthen the company's cash reserves and assist in advancing its pipeline development and international strategy [1]

Core Viewpoint - Changchun High-tech (000661) has made progress in the GenSci098 injection project by signing an exclusive licensing agreement, receiving an initial payment of $70 million from Yarrow [1] Group 1: Company Developments - The company's subsidiary, Jinsai Pharmaceutical, through its wholly-owned subsidiary, Saizeng Medical, has entered into an exclusive licensing agreement with Yarrow for the GenSci098 injection project [1] - GenSci098 injection is a humanized TSH receptor antagonist monoclonal antibody developed by Jinsai Pharmaceutical, classified as a first-class new drug for therapeutic biological products [1]

证券代码：000661 证券简称：长春高新 公告编号：2026-003 长春高新技术产业（集团）股份有限公司 关于 GenSci098 注射液项目签署独家许可协议的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 重要提示： 二、有关 GenSci098 注射液项目 1 GenSci098 注射液是金赛药业自主研发的一种人源化促甲状腺激素受体 （TSHR）拮抗型单克隆抗体，为治疗用生物制品 1 类新药。通过特异性与甲状 腺或球后组织内 TSHR 结合，阻断其与自身抗体结合，进而抑制甲状腺激素的合 成和释放、抑制甲状腺细胞的增殖、阻止 HA 和炎症因子释放，从而发挥改善甲 亢的作用，并同时具有改善突眼的作用。本品临床前数据、在研的甲状腺眼病 （TED）的 I 期临床研究以及同靶点其他药物的临床数据表明，GenSci098 有潜 力作为一种治疗弥漫性毒性甲状腺肿的新型治疗手段，相关临床试验可以推动后 续该产品针对弥漫性毒性甲状腺肿人群的临床开发。 目前，GenSci098 注射液已于 2024 年 8 月同步在中国大陆及美国获批开展 用于甲状腺相关眼病（T ...

Core Viewpoint - The company has received a significant upfront payment of $70 million from Yarrow Bioscience for the exclusive licensing agreement related to the GenSci098 injection project, which is set to undergo clinical trials for thyroid-related eye disease and Graves' disease in China and the United States [1] Group 1 - The company’s subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd., has a wholly-owned subsidiary, Shanghai Saizeng Medical Technology Co., Ltd., which is involved in the licensing agreement [1] - The GenSci098 injection has been approved to commence clinical trials for thyroid eye disease (TED) in both mainland China and the United States starting August 2024 [1] - The injection is also set to be approved for clinical trials for Graves' disease (GD) in mainland China by October 2025 [1]

Core Viewpoint - Changchun High-tech announced that its subsidiary, Jinsai Pharmaceutical, has signed an exclusive licensing agreement with Yarrow for the GenSci098 injection project, which will enhance the company's cash reserves and support its pipeline development and international strategy [1] Group 1 - The exclusive licensing agreement was signed on December 15, 2025, granting Yarrow global exclusive development rights for GenSci098 injection outside of Greater China [1] - The first payment of $70 million is expected to be received on January 14, 2026, although the actual amount will be subject to taxes and fees [1] - GenSci098 injection is a self-developed product by Jinsai Pharmaceutical, which has already been approved for clinical trials in both China and the United States [1]

Group 1 - The core issue raised by investors is the reported shortage of Changchun High-tech's long-acting growth hormone after its inclusion in the medical insurance system [1] - Changchun High-tech responded by stating that it will manage the delivery of products based on market demand and price changes [1]

Core Viewpoint - Changchun Gaoxin (000661) stated that the company will reasonably arrange shipments based on market demand and product price changes [1] Group 1 - The company is actively engaging with investors through an interactive platform [1] - The company emphasizes the importance of market demand in its operational decisions [1] - Product price fluctuations will also influence the company's shipment arrangements [1]

Core Viewpoint - Changchun High-tech's stock price has shown a significant increase this year, with a notable rise in recent trading days, despite a decline over the past two months [1][2]. Group 1: Stock Performance - As of January 13, Changchun High-tech's stock price increased by 2.01%, reaching 105.65 CNY per share, with a trading volume of 7.11 billion CNY and a turnover rate of 1.72% [1]. - Year-to-date, the stock price has risen by 14.15%, with a 10.12% increase over the last five trading days and a 12.81% increase over the last 20 days, while it has decreased by 12.88% over the last 60 days [1]. Group 2: Financial Performance - For the period from January to September 2025, Changchun High-tech reported a revenue of 9.807 billion CNY, a year-on-year decrease of 5.60%, and a net profit attributable to shareholders of 1.165 billion CNY, down 58.23% year-on-year [2]. - The company has distributed a total of 4.791 billion CNY in dividends since its A-share listing, with 3.259 billion CNY distributed over the last three years [3]. Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders for Changchun High-tech was 104,100, a decrease of 4.63% from the previous period, with an average of 3,840 circulating shares per shareholder, an increase of 4.85% [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited is the third largest, holding 9.7451 million shares, an increase of 1.307 million shares from the previous period [3].

Market Overview - The biopharmaceutical sector experienced a slight decline of 0.06% on January 12, with Sanofi leading the drop [1] - The Shanghai Composite Index closed at 4165.29, up 1.09%, while the Shenzhen Component Index closed at 14366.91, up 1.75% [1] Stock Performance - Notable gainers in the biopharmaceutical sector included: - Dongbao Biological (300239) with a closing price of 6.60, up 10.92% and a trading volume of 575,100 shares, totaling 366 million yuan [1] - Changchun High-tech (000661) closed at 103.57, up 5.79%, with a trading volume of 169,400 shares, totaling 1.725 billion yuan [1] - ST Weiming (002581) closed at 7.83, up 4.96%, with a trading volume of 71,500 shares, totaling 54.3049 million yuan [1] - Conversely, significant decliners included: - Sanofi (688336) closed at 59.81, down 6.25%, with a trading volume of 93,200 shares, totaling 560 million yuan [2] - Teva Biopharma (688278) closed at 76.96, down 4.50%, with a trading volume of 41,600 shares, totaling 323 million yuan [2] - Aidi Pharmaceutical (688488) closed at 16.90, down 4.41%, with a trading volume of 98,600 shares, totaling 168 million yuan [2] Capital Flow - The biopharmaceutical sector saw a net outflow of 240 million yuan from institutional investors, while retail investors contributed a net inflow of 272 million yuan [2] - Key stocks with significant capital flow included: - Changchun High-tech (000661) had a net inflow of 122 million yuan from institutional investors, while retail investors saw a net outflow of 77.57 million yuan [3] - Dongbao Biological (300239) experienced a net inflow of 22.51 million yuan from institutional investors, with retail investors also seeing a net outflow of 10.81 million yuan [3] - Sanofi (688336) had a net inflow of 21.21 million yuan from institutional investors, while retail investors had a net inflow of 28.87 million yuan [3]